| locally advanced (laHNSCC) | metastatic-recurrent HNSCC (mHNSCC) | |||||
| laHNSCC - 1st line (L1) | mHNSCC - L1 - all population | mHNSCC - L1 - PDL1 positive | mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | |
| immune chekpoint inhibitors | ||||||
| anti-PD-(L)1 | ||||||
| avelumab based treatment | ||||||
| avelumab alone | JAVELIN Head and Neck 100 | |||||
| durvalumab based treatment | ||||||
| durvalumab alone | EAGLE ... | |||||
| nivolumab based treatment | ||||||
| nivolumab alone | CheckMate 141 | |||||
| pembrolizumab based treatment | ||||||
| pembrolizumab alone | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... | KEYNOTE-040 ... | KEYNOTE-040 ... | ||
| pembrolizumab plus 5FU plus platin | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... | ||||
| Immune checkpoint association | ||||||
| durvalumab plus tremelimumab | EAGLE ... | CONDOR ... CONDOR ... | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
